JAZZ - Latest News
Jazz Pharmaceuticals plc (JAZZ), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $14.45B. Trailing twelve-month P/E ratio is 482.77. Beta to the broader market is 0.33.
The article list below shows the most recent JAZZ headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent JAZZ Headlines
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com - Jun 30, 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
fool.com - Jun 23, 2026
Zepzelca's failed trial doesn't derail Jazz's growth strategy. First-line adoption is becoming Zepzelca's biggest opportunity.
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
zacks.com - Jun 18, 2026
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
benzinga.com - Jun 17, 2026
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
reuters.com - Jun 17, 2026
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific ant
How News Affects JAZZ Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track JAZZ's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked JAZZ news questions
- What is the latest JAZZ news headline?
- The most recent JAZZ headline (Jun 30, 2026) is "Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the JAZZ news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What JAZZ news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual JAZZ options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.